657 related articles for article (PubMed ID: 34381196)
21. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.
Emmerson PJ; Wang F; Du Y; Liu Q; Pickard RT; Gonciarz MD; Coskun T; Hamang MJ; Sindelar DK; Ballman KK; Foltz LA; Muppidi A; Alsina-Fernandez J; Barnard GC; Tang JX; Liu X; Mao X; Siegel R; Sloan JH; Mitchell PJ; Zhang BB; Gimeno RE; Shan B; Wu X
Nat Med; 2017 Oct; 23(10):1215-1219. PubMed ID: 28846098
[TBL] [Abstract][Full Text] [Related]
22. Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets.
Rochette L; Zeller M; Cottin Y; Vergely C
Trends Endocrinol Metab; 2020 Dec; 31(12):939-951. PubMed ID: 33172749
[TBL] [Abstract][Full Text] [Related]
23. Overview of growth differentiation factor 15 (GDF15) in metabolic diseases.
Li J; Hu X; Xie Z; Li J; Huang C; Huang Y
Biomed Pharmacother; 2024 May; 176():116809. PubMed ID: 38810400
[TBL] [Abstract][Full Text] [Related]
24. GDF15, an update of the physiological and pathological roles it plays: a review.
Assadi A; Zahabi A; Hart RA
Pflugers Arch; 2020 Nov; 472(11):1535-1546. PubMed ID: 32936319
[TBL] [Abstract][Full Text] [Related]
25. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.
Yang L; Chang CC; Sun Z; Madsen D; Zhu H; Padkjær SB; Wu X; Huang T; Hultman K; Paulsen SJ; Wang J; Bugge A; Frantzen JB; Nørgaard P; Jeppesen JF; Yang Z; Secher A; Chen H; Li X; John LM; Shan B; He Z; Gao X; Su J; Hansen KT; Yang W; Jørgensen SB
Nat Med; 2017 Oct; 23(10):1158-1166. PubMed ID: 28846099
[TBL] [Abstract][Full Text] [Related]
26. GDF15 in Appetite and Exercise: Essential Player or Coincidental Bystander?
Klein AB; Kleinert M; Richter EA; Clemmensen C
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34849709
[TBL] [Abstract][Full Text] [Related]
27. Camptothecin effectively treats obesity in mice through GDF15 induction.
Lu JF; Zhu MQ; Xie BC; Shi XC; Liu H; Zhang RX; Xia B; Wu JW
PLoS Biol; 2022 Feb; 20(2):e3001517. PubMed ID: 35202387
[TBL] [Abstract][Full Text] [Related]
28. GDF15 promotes weight loss by enhancing energy expenditure in muscle.
Wang D; Townsend LK; DesOrmeaux GJ; Frangos SM; Batchuluun B; Dumont L; Kuhre RE; Ahmadi E; Hu S; Rebalka IA; Gautam J; Jabile MJT; Pileggi CA; Rehal S; Desjardins EM; Tsakiridis EE; Lally JSV; Juracic ES; Tupling AR; Gerstein HC; Paré G; Tsakiridis T; Harper ME; Hawke TJ; Speakman JR; Blondin DP; Holloway GP; Jørgensen SB; Steinberg GR
Nature; 2023 Jul; 619(7968):143-150. PubMed ID: 37380764
[TBL] [Abstract][Full Text] [Related]
29. Targeting the divergent TGFβ superfamily cytokine MIC-1/GDF15 for therapy of anorexia/cachexia syndromes.
Tsai VW; Brown DA; Breit SN
Curr Opin Support Palliat Care; 2018 Dec; 12(4):404-409. PubMed ID: 30382947
[TBL] [Abstract][Full Text] [Related]
30. Overview of growth differentiation factor 15 in metabolic syndrome.
Asrih M; Wei S; Nguyen TT; Yi HS; Ryu D; Gariani K
J Cell Mol Med; 2023 May; 27(9):1157-1167. PubMed ID: 36992609
[TBL] [Abstract][Full Text] [Related]
31. The GDF15-GFRAL axis mediates chemotherapy-induced fatigue in mice.
Chelette B; Chidomere CL; Dantzer R
Brain Behav Immun; 2023 Feb; 108():45-54. PubMed ID: 36427806
[TBL] [Abstract][Full Text] [Related]
32. GDF15 and Cardiac Cells: Current Concepts and New Insights.
Rochette L; Dogon G; Zeller M; Cottin Y; Vergely C
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445593
[TBL] [Abstract][Full Text] [Related]
33. LPS induces rapid increase in GDF15 levels in mice, rats, and humans but is not required for anorexia in mice.
Patel AR; Frikke-Schmidt H; Bezy O; Sabatini PV; Rittig N; Jessen N; Myers MG; Seeley RJ
Am J Physiol Gastrointest Liver Physiol; 2022 Feb; 322(2):G247-G255. PubMed ID: 34935522
[TBL] [Abstract][Full Text] [Related]
34. Creation of a Peptide Antagonist of the GFRAL-RET Receptor Complex for the Treatment of GDF15-Induced Malaise.
Borner T; Tinsley IC; Milliken BT; Doebley SA; Najjar NR; Kerwood DJ; De Jonghe BC; Hayes MR; Doyle RP
J Med Chem; 2023 Aug; 66(16):11237-11249. PubMed ID: 37506293
[TBL] [Abstract][Full Text] [Related]
35. Knocking on GDF15's door for the treatment of type 2 diabetes mellitus.
Aguilar-Recarte D; Barroso E; Palomer X; Wahli W; Vázquez-Carrera M
Trends Endocrinol Metab; 2022 Nov; 33(11):741-754. PubMed ID: 36151002
[TBL] [Abstract][Full Text] [Related]
36. GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer.
Ahmed DS; Isnard S; Lin J; Routy B; Routy JP
J Cancer; 2021; 12(4):1125-1132. PubMed ID: 33442410
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise.
Klein AB; Nicolaisen TS; Ørtenblad N; Gejl KD; Jensen R; Fritzen AM; Larsen EL; Karstoft K; Poulsen HE; Morville T; Sahl RE; Helge JW; Lund J; Falk S; Lyngbæk M; Ellingsgaard H; Pedersen BK; Lu W; Finan B; Jørgensen SB; Seeley RJ; Kleinert M; Kiens B; Richter EA; Clemmensen C
Nat Commun; 2021 Feb; 12(1):1041. PubMed ID: 33589633
[TBL] [Abstract][Full Text] [Related]
38. Weight Loss Induced by Bariatric Surgery Restricts Hepatic
Adolph TE; Grabherr F; Mayr L; Grander C; Enrich B; Moschen AR; Tilg H
J Obes; 2018; 2018():7108075. PubMed ID: 30533221
[TBL] [Abstract][Full Text] [Related]
39. GDNF family receptor alpha-like antagonist antibody alleviates chemotherapy-induced cachexia in melanoma-bearing mice.
Lee BY; Jeong J; Jung I; Cho H; Jung D; Shin J; Park JK; Park E; Noh S; Shin S; Kang S; Heo JI; Baek MC; Yea K
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1441-1453. PubMed ID: 37017344
[TBL] [Abstract][Full Text] [Related]
40. Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice.
Suriben R; Chen M; Higbee J; Oeffinger J; Ventura R; Li B; Mondal K; Gao Z; Ayupova D; Taskar P; Li D; Starck SR; Chen HH; McEntee M; Katewa SD; Phung V; Wang M; Kekatpure A; Lakshminarasimhan D; White A; Olland A; Haldankar R; Solloway MJ; Hsu JY; Wang Y; Tang J; Lindhout DA; Allan BB
Nat Med; 2020 Aug; 26(8):1264-1270. PubMed ID: 32661391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
